How big is Halozyme Therapeutics, Inc.?

As of Jun 18, Halozyme Therapeutics, Inc. has a market capitalization of $6.54 billion, with net sales of $1.08 billion and a net profit of $485.36 million over the latest four quarters.

Market Cap: As of Jun 18, Halozyme Therapeutics, Inc. has a market capitalization of 6,544.27 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Halozyme reported net sales of 1,084.30 million and a net profit of 485.36 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 363.82 million, while total assets were reported at 2,163.88 million.

What does Halozyme Therapeutics, Inc. do?

Halozyme Therapeutics, Inc. is a biotechnology company specializing in oncology therapies, with a market cap of approximately $6.54 billion. As of March 2025, it reported net sales of $265 million and a net profit of $118 million.

Overview:<BR>Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies within the Pharmaceuticals & Biotechnology industry, categorized as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 265 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 118 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 6,544.27 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 14.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.57 <BR>Return on Equity: 100.64% <BR>Price to Book: 13.57<BR><BR>Contact Details:<BR>Address: 11388 Sorrento Valley Rd, SAN DIEGO CA: 92121-1345 <BR>Tel: ['1 858 7948889', '1 858 704-8122'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.halozyme.com/

Should I buy, sell or hold Halozyme Therapeutics, Inc.?

Who are in the management team of Halozyme Therapeutics, Inc.?

As of March 2022, the management team of Halozyme Therapeutics, Inc. includes Independent Chairman Ms. Connie Matsui, CEO Dr. Helen Torley, and several Independent Directors: Dr. Jean-Pierre Bizzari, Ms. Bernadette Connaughton, Mr. James Daly, Mr. Jeffrey Henderson, and Mr. Kenneth Kelley.

As of March 2022, the management team of Halozyme Therapeutics, Inc. includes the following individuals:<BR><BR>- Ms. Connie Matsui, who serves as the Independent Chairman of the Board.<BR>- Dr. Helen Torley, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Jean-Pierre Bizzari, who is an Independent Director.<BR>- Ms. Bernadette Connaughton, who is also an Independent Director.<BR>- Mr. James Daly, another Independent Director.<BR>- Mr. Jeffrey Henderson, who serves as an Independent Director.<BR>- Mr. Kenneth Kelley, who is also an Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and key executive leadership.

Is Halozyme Therapeutics, Inc. overvalued or undervalued?

As of October 17, 2025, Halozyme Therapeutics, Inc. is fairly valued with a P/E ratio of 14, strong growth potential indicated by a PEG ratio of 0.22, and a remarkable ROE of 100.64%, outperforming peers and the S&P 500 over the past year.

As of 17 October 2025, the valuation grade for Halozyme Therapeutics, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 14, an EV to EBITDA of 10.96, and a PEG ratio of 0.22, which suggests strong growth potential relative to its price.<BR><BR>In comparison to peers, Halozyme's P/E ratio of 14 is lower than Illumina, Inc. at 19.09 and BioMarin Pharmaceutical, Inc. at 15.17, indicating it may be a more attractive investment relative to these companies. Additionally, the company's ROE of 100.64% is significantly higher than the industry average, highlighting its efficiency in generating profits. Over the past year, Halozyme has returned 28.21%, outperforming the S&P 500's return of 14.08%, reinforcing its competitive position in the market.

Is Halozyme Therapeutics, Inc. technically bullish or bearish?

As of October 31, 2025, Halozyme Therapeutics, Inc. shows a mildly bullish trend, with daily moving averages and Bollinger Bands indicating bullish signals, despite mixed MACD readings and recent underperformance compared to the S&P 500 over the month.

As of 31 October 2025, the technical trend for Halozyme Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a mildly bearish stance, while the monthly MACD remains bullish. The daily moving averages are mildly bullish, and Bollinger Bands show bullish signals for both weekly and monthly time frames. However, the KST and Dow Theory indicate no clear trend on both weekly and monthly levels. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week with a return of 3.34% compared to 0.71%, but it has underperformed over the past month with a return of -1.35% against the S&P 500's 1.92%. Year-to-date, the stock has a strong return of 42.33% versus the S&P 500's 16.30%. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and Bollinger Bands.